TriSalus Life Sciences, Inc. (NASDAQ:TLSI) reported that Chief Regulatory Officer Jennifer Stevens sold a total of 3,530 shares of the company’s common stock in a sequence of transactions conducted between March 11 and March 16, 2026. The filings show the stock was sold at prices ranging from $4.09 to $4.13, producing total proceeds of about $14,509.
Transaction details are laid out in the company filing. On March 11, Stevens sold 1,204 shares at $4.13 per share. The following day, March 12, she sold 1,552 shares at $4.09 per share. The final disposition came on March 16, when she sold 774 shares at $4.12 per share.
The disclosure specifies that the share sales were executed to satisfy tax obligations associated with the vesting of restricted stock units and that the sales were not discretionary. After these transactions, Stevens is recorded as directly owning 124,110 shares of TriSalus common stock.
Market context provided in the filing notes that TLSI shares are trading at $3.92, reflecting a year-to-date decline of 44.7 percent. An InvestingPro analysis referenced in the filing characterizes the stock as trading below its Fair Value, indicating it may be undervalued at current levels. The company is scheduled to report quarterly results on March 26, six days after the last disclosed insider sale.
Beyond the insider transactions, TriSalus supplied recent operational and financial updates that offer additional context for investors.
For the fourth quarter of 2025, TriSalus reported revenue of $13.2 million, a 60 percent increase from the comparable quarter the prior year. The company attributed this growth to improved manufacturing efficiencies and a strategic expansion of its product offerings. Despite the increase in revenue, TriSalus recorded a net operating loss of $3.3 million for the quarter, though this represents an improvement from a $7.6 million loss in the same quarter a year earlier. On a fiscal-year basis, TriSalus reported revenue of $45 million for 2025, a 53 percent increase over fiscal 2024.
Following these results, Jones Trading reiterated a Buy rating on TriSalus and maintained a price target of $11.00. The company also published preclinical research in Frontiers in Oncology evaluating its Pressure-Enabled Drug Delivery technology for administering nelitolimod in liver tumor models. That study compared the technology’s performance with conventional delivery methods using both porcine and murine liver tumor models.
These disclosures combine an insider liquidity event tied to RSU vesting with recent operational progress and upcoming earnings, providing shareholders and market observers with multiple near-term datapoints to consider.